Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Table 2 Inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia

*This may be repeated if patients do not achieve CR/CRi after cycle 1, though cycle length after cycle 1 should be 28 days
^#For patients planning to receive an allogeneic transplant, treatment with inotuzumab ozogamicin should be limited to 2 cycles of induction or the fewest number of cycles required to achieve a CR/CRi (if CR/CRi not achieved after 2 cycles)

ISSN: 1756-8722